US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

43.36

+1.022.41%

Post-market: 43.360.00000.00%16:10 EDT

Volume:513

Turnover:22.27K

Market Cap:32.52M

PE:- -

High:43.40

Open:43.40

Low:43.28

Close:42.34

52wk High:43.40

52wk Low:29.50

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.75

T/O Rate:0.07%

Dividend:0.14

Dividend Rate:0.33%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Natera Q2 EPS USD -0.47

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring

Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289

THOMSON REUTERS

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Agenus Q2 Revenue Rises on Access and Royalty Income

Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million

Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln

THOMSON REUTERS

Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50

THOMSON REUTERS

Ligand Pharmaceuticals Q2 EPS USD 2.22

THOMSON REUTERS

Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Natera Seeks Japan PMDA Approval for Signatera Test in Muscle-Invasive Bladder Cancer

Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million

Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows

Guardant Health is Maintained at Overweight by Morgan Stanley

Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.3608,"timestamp":1787688000000,"preClose":42.3399,"halted":0,"volume":513,"hourTrading":{"tag":"盘后","latestPrice":43.3608,"preClose":43.3608,"latestTime":"16:10 EDT","volume":6,"amount":260.1648,"timestamp":1787688604286,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02411200782240859,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":1.0209,"latestTime":"08-25 16:22:53 EDT","open":43.4001,"high":43.4001,"low":43.275,"amount":22271,"amplitude":0.002955,"askPrice":65.18,"askSize":100,"bidPrice":21.73,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":42.3399,"sharesOutstanding":650000,"nav":43.201,"aum":32400497.63,"dividendRate":0.003321,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.3608,"preClose":43.3608,"latestTime":"16:10 EDT","volume":6,"amount":260.1648,"timestamp":1787688604286,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.751318,"impliedVol":0.0938,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.751318,"shares":750000,"dividePrice":0.144,"high":43.4001,"amplitude":0.002955,"preClose":42.3399,"low":43.275,"week52Low":29.5,"pbRate":"--","week52High":43.4001,"institutionHeld":0,"latestPrice":43.3608,"committee":0.333333,"eps":0,"divideRate":0.003321,"volume":513,"delay":0,"ttmEps":0,"open":43.4001,"prevYearClose":36.3062,"prevWeekClose":43.11,"prevMonthClose":38.8312,"prevQuarterClose":39.9651,"fiveDayClose":40.9918,"twentyDayClose":39.1286,"sixtyDayClose":34.2035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657657601","title":"Natera Q2 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657601","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657601?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046762,"startTime":"0","endTime":"0","summary":"BRIEF-Natera Q2 EPS USD -0.47Aug 06 (Reuters) - Natera Q2 revenue USD 752.8 million vs. IBES estimate USD 660.7 million.Q2 income from operations USD -75.8 millionQ2 operating expenses USD 555.3 millionQ2 net income USD -67 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXW22CMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU2065169927.USD","LU2065170008.USD","LU0053671581.USD","LU2065731478.USD","NTRA","LU2065171402.SGD","LU2264538146.SGD","GNOM","LU1988902786.USD","LU0345770993.USD","LU2065171311.SGD","BK4139","LU0963586101.USD","LU2324357040.USD","HELX","LU0012050646.USD","LU0106261612.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365692","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365692?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:40","pubTimestamp":1786034422,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ligand Pharma (LGND), Protagonist Therapeutics (PT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-protagonist-therapeutics-ptgx-and-zoetis-zts-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-protagonist-therapeutics-ptgx-and-zoetis-zts-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z9505.USD","LU1721429741.USD","HELX","BK4534","LU1721429402.USD","LU0385154629.USD","LU0107464264.USD","LU0058720904.USD","LU1559883803.SGD","XBI","LU1059921491.USD","LU1941712348.USD","LU2028103732.USD","HCSG","LU0128526141.USD","LU0345774391.USD","LU0471298777.SGD","LU0566484027.USD","BK4585","LU2111349929.HKD","LU2360106947.USD","BK4137","LU1236620834.HKD","LABU","BK4588","LU0345774631.USD","LU0289739699.SGD","LU0158827781.USD","LU2271345857.HKD","XLV","GB00BDT5M118.USD","LU0029874061.USD","BK4007","LU0471298694.HKD","LU1236620750.USD","LU2023251221.USD","LGND","ZTS","BK4139","LU1941712264.USD","BK4581","LU2308191902.HKD","LU2089284900.SGD","IE0009354923.USD","PTGX","PAWZ","LU0079474960.USD","LU2089283258.USD","LU0158827948.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657188656","title":"Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2657188656","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657188656?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:39","pubTimestamp":1786034367,"startTime":"0","endTime":"0","summary":"Natera Inc. ($NTRA) announced an update on their ongoing clinical study. The SCORE-NHL study, officially titled “Sample Collection for Ongoing Rese...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nateras-score-nhl-study-builds-long-term-value-in-lymphoma-monitoring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nateras-score-nhl-study-builds-long-term-value-in-lymphoma-monitoring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1988902786.USD","LU2065731478.USD","NTRA","LU2065171402.SGD","LU1064131342.USD","LU0012050646.USD","LU0963586101.USD","HELX","LU0345770993.USD","LU2065169927.USD","GNOM","LU2264538146.SGD","LU2065171311.SGD","LU2065170008.USD","BK4139","LU0345770308.USD","LU2324357040.USD","LU0053671581.USD","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657392655","title":"Ligand Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $358 from $289","url":"https://stock-news.laohu8.com/highlight/detail?id=2657392655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657392655?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:59","pubTimestamp":1786031999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nAZN4TC72M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","LGND","HELX","LU0566484027.USD","BK4007","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653875","title":"Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653875?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:12","pubTimestamp":1786029141,"startTime":"0","endTime":"0","summary":"Cancer drugmaker Genmab's H1 revenue rises, lifts FY outlookOverviewDenmark biotech firm's H1 2026 revenue rose 25% yr/yr, driven by higher royalties and salesOperating profit for H1 2026 increased sl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","LU0566484027.USD","BK4139","XNCR","HELX","IE0009354923.USD","BK4007","LU1559883803.SGD","LGND","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632403","title":"Ligand Pharmaceuticals Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632403","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632403?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings SummaryLigand Pharmaceuticals IncorporatedLGND.OQreported quarterly adjusted earnings of $2.37 per share fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","HELX","BK4139","LGND","LU0566484027.USD","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635177","title":"Agenus Q2 Revenue Rises on Access and Royalty Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635177","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635177?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:44","pubTimestamp":1786016679,"startTime":"0","endTime":"0","summary":"Agenus Q2 revenue rises on access and royalty incomeOverviewImmuno-oncology drug developer's Q2 revenue rose yr/yr, driven by higher royalty and access program revenueAgenus completed $85 mln private ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","XNCR","BK4007","HELX","BK4139","RCUS","LU1559883803.SGD","LGND","IE0009354923.USD","AGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638485","title":"Ligand Q2 FY26 Adjusted EPS Climbs 48% to $2.37; Revenue Rises 34% to $63.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638485","media":"Reuters","labels":["shareholding","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638485?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:09","pubTimestamp":1786014590,"startTime":"0","endTime":"0","summary":"Ligand Q2 FY26 adjusted EPS climbs 48% to $2.37; revenue rises 34% to $63.7 millionLigand Pharmaceuticals posted Q2 GAAP net income of $48.51 million, or $2.22 per diluted share, versus $4.85 million,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3CnHjm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HELX","IE0009354923.USD","LU1559883803.SGD","LU0566484027.USD","BK4007","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657902633","title":"Ligand Pharmaceuticals Incorporated - 2026 Total Revenue Guidance $270 Mln to $310 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657902633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657902633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","BK4139","HELX","IE0009354923.USD","BK4007","LU1559883803.SGD","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763390","title":"Ligand Pharmaceuticals Incorporated - 2026 Adj EPS Guidance $9 to $9.50, Previously $8.50 to $9.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763390?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009354923.USD","LU1559883803.SGD","BK4007","LGND","BK4139","LU0566484027.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680486","title":"Ligand Pharmaceuticals Q2 EPS USD 2.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX7054G2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","LGND","LU1559883803.SGD","HELX","IE0009354923.USD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508493","title":"Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508493","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508493?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:35","pubTimestamp":1785980152,"startTime":"0","endTime":"0","summary":"Natera CFO Michael Burkes Brophy disposes of 795 common shares worth $215,449.79Natera CFO Michael Burkes Brophy sold 795 common shares on Aug. 3-4.Sales priced at USD 267.99 to USD 274.22 per share.H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6sQPKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","HELX","LU2264538146.SGD","LU0963586101.USD","LU1064131342.USD","LU0053671581.USD","LU0345770308.USD","LU0012050646.USD","BK4139","NTRA","LU2324357040.USD","LU2065169927.USD","GNOM","LU2065731478.USD","LU2065171311.SGD","LU0106261612.USD","LU2065170008.USD","LU0345770993.USD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","GNMX","PTH","LU0320765992.SGD","BK4196","LFSC","BK4585","EKG","BK4551","BK4588","FFOX","LU0889565916.HKD","GH","LU0109394709.USD","HELX","GNOM","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657208075","title":"Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657208075","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657208075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960518,"startTime":"0","endTime":"0","summary":"Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlookOverviewUS dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demandCompany raised 2026 full-year net p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","ACAD","SNDX","BK4139","LU2065170008.USD","LU2065171311.SGD","ARQT","PSCH","LU2065171402.SGD","HELX","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LFSC","BK4139","BK4532","UTHR","LU1699723380.USD","KRYS","TVTX","HELX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510294","title":"Natera Seeks Japan PMDA Approval for Signatera Test in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510294","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510294?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924184,"startTime":"0","endTime":"0","summary":"Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancerNatera filed Signatera with Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbyDBmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","LU1064131342.USD","LU0963586101.USD","HELX","LU1988902786.USD","LU2065170008.USD","LU0053671581.USD","BK4139","LU2324357040.USD","LU2065169927.USD","LU0345770993.USD","LU2065731478.USD","LU0106261612.USD","NTRA","LU2065171402.SGD","GNOM","LU2065171311.SGD","LU0012050646.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657187598","title":"Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657187598","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657187598?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:43","pubTimestamp":1785883420,"startTime":"0","endTime":"0","summary":"Ligand CLO, Secretary Andrew Reardon reports disposal of 5,000 common shares worth $1.44 millionLigand Pharmaceuticals CLO and Secretary Andrew Reardon exercised employee stock options for 5,000 share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7VGDr6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ligand CLO, Secretary Andrew Reardon Reports Disposal of 5,000 Common Shares Worth $1.44 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","HELX","BK4139","LGND","LU0566484027.USD","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","MEDI","KRYS","HRMY","BK4139","RARE","BK4585","BK4588","PSCH","HELX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556059","title":"Guardant Health is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556059?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:44","pubTimestamp":1785847440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","LU0109394709.USD","FFOX","GH","HELX","BK4588","BK4535","GNOM","BK4551","LU0889565916.HKD","LU0320765992.SGD","LFSC","GDOC","EKG","BK4585","GNMX","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556333","title":"Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556333?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:22","pubTimestamp":1785846120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}